Sativex Shows Significant Spasticity Improvement, UK

Main Category: Multiple Sclerosis
Article Date: 15 Mar 2009 - 1:00 PDT

email to a friend   printer friendly   opinions  

GW Pharmaceuticals has announced plans to submit an application to market its cannabis-based multiple sclerosis (MS) treatment, Sativex, in the UK.

This follows the announcement this week of study results, which showed that in nearly three-quarters of people with MS taking a fixed dose of Sativex, there was an improvement of more than 30% in levels of spasticity.

The Phase III study investigated 573 people with MS who were affected by spasticity and had not responded to existing therapies.

Spasticity is one of the most common symptoms in MS. There are several treatments available for those who are affected by spasticity, but for some, these are ineffective.

Dr Lee Dunster, Head of Research at the MS Society, said: "We have been monitoring Sativex for many months now and are pleased with these positive results.

"Making Sativex widely available could help alleviate one of the most distressing symptoms of MS and this is especially good news for people with progressive forms of the condition."

Read more about the recent Sativex results

MS Society

• Additional
• References
• Citations